Aldeyra therapeutics, inc. (ALDX)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Jun'14Mar'14Dec'13
ASSETS
Current assets:
Cash and cash equivalents

15,542

16,425

25,604

7,399

5,297

3,357

-

-

-

2,023

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash equivalent - reverse repurchase agreements

23,000

28,000

26,000

32,000

39,000

44,000

-

-

-

18,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Marketable securities

22,833

28,938

24,567

30,057

37,826

46,242

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash and cash equivalents

-

-

-

-

-

-

18,008

24,605

20,963

-

33,103

14,609

19,302

12,015

14,568

17,607

10,148

14,648

30,618

33,569

15,721

8,527

11,535

2,145

3,262

Marketable securities

-

-

-

-

-

-

17,133

17,072

17,974

22,923

14,807

11,210

11,909

12,897

14,307

14,940

12,877

12,941

-

-

-

-

-

-

-

Prepaid expenses and other current assets

1,375

1,804

849

3,398

4,872

1,169

1,702

1,392

1,666

1,018

1,141

521

260

218

250

260

283

497

607

266

177

232

269

9

8

Total current assets

62,751

75,168

77,020

72,855

86,996

94,769

36,845

43,071

40,605

43,965

49,052

26,342

31,473

25,131

29,125

32,808

23,309

28,088

31,225

33,836

15,898

8,759

11,805

2,155

3,270

Debt issuance costs

-

-

-

492

538

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets

152

201

248

294

377

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs

-

-

-

-

-

86

43

-

-

165

138

77

-

-

-

-

45

36

36

-

20

14

0

735

472

Fixed assets, net

124

148

172

196

215

235

243

214

170

43

38

47

58

56

65

75

81

80

88

40

13

12

-

-

-

Total assets

63,029

75,518

77,440

73,839

88,128

95,091

37,131

43,286

40,775

44,174

49,229

26,467

31,531

25,187

29,191

32,883

23,436

28,204

31,350

33,877

15,931

8,787

11,805

2,890

3,743

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable

1,072

808

572

2,773

4,013

3,051

3,442

802

1,618

1,000

485

762

694

275

733

823

578

851

743

629

406

341

556

165

341

Convertible notes payable - related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

155

85

Accrued interest on convertible notes payable - related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

4

2

Accrued expenses

3,641

11,873

11,324

3,403

5,257

5,421

3,746

4,159

1,815

2,236

1,507

1,038

1,520

1,946

1,476

1,084

1,035

1,186

630

451

436

908

211

133

117

Current portion of operating lease liabilities

172

226

218

211

221

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

155

-

-

-

-

-

-

0

604

394

Current portion of credit facility

-

-

-

-

-

-

465

348

232

116

426

310

193

77

426

310

193

77

-

310

193

77

407

232

58

Total current liabilities

4,886

12,907

12,116

6,389

9,491

8,473

7,653

5,310

3,666

3,353

2,419

2,111

2,409

2,299

2,636

2,373

1,807

2,115

1,373

1,391

1,036

1,327

1,174

691

605

Long-term debt

14,669

14,528

14,386

-

-

-

882

995

1,107

1,220

905

1,016

1,127

1,238

883

992

1,101

1,211

1,281

961

1,068

1,175

815

972

1,129

Operating lease liabilities, net of current portion

-

-

58

116

156

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

132

253

Convertible preferred stock warrant liabilities - related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,626

3,265

Total liabilities

19,556

27,435

26,561

6,505

9,648

8,473

8,536

6,305

4,774

4,573

3,324

3,128

3,536

3,537

3,519

3,365

2,909

3,326

2,655

2,352

2,104

2,503

1,990

4,027

5,647

Commitments and contingencies (Notes 13 and 14)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

38,508

38,317

Stockholders' equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

-

0

Common stock, voting, $0.001 par value; 150,000,000 authorized and 29,506,829 and 28,656,832 shares issued and outstanding, respectively

29

28

27

26

26

26

20

20

19

19

19

15

15

12

12

12

9

9

9

9

6

5

-

-

-

Additional paid-in capital

252,615

247,409

237,047

234,779

232,605

225,136

156,481

154,051

144,036

139,241

138,574

111,030

110,377

98,938

98,302

97,372

84,084

83,478

82,931

82,395

-

52,790

-

-

-

Accumulated other comprehensive income

57

5

5

13

6

-9

-5

-2

-16

-17

-1

-4

-4

0

6

4

1

-8

-

-

-

-

-

-

-

Additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

62,467

-

51,867

1,276

1,102

Accumulated deficit

-209,230

-199,361

-186,201

-167,486

-154,159

-138,535

-127,901

-117,089

-108,038

-99,641

-92,687

-87,701

-82,392

-77,301

-72,649

-67,871

-63,569

-58,601

-54,246

-50,880

-48,648

-46,511

-42,057

-

-41,324

Deficit accumulated during the development stage

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

40,922

-

Total stockholders’ equity

43,472

48,082

50,879

67,333

78,479

86,617

28,595

36,980

36,001

39,601

45,904

23,339

27,995

21,649

25,671

29,517

20,527

24,878

28,695

31,524

13,826

6,284

9,814

-39,645

-40,221

Total liabilities and stockholders’ equity

63,029

75,518

77,440

73,839

88,128

95,091

37,131

43,286

40,775

44,174

49,229

26,467

31,531

25,187

29,191

32,883

23,436

28,204

31,350

33,877

15,931

8,787

11,805

2,890

3,743